The efficacy of alpha‑ketoglutarate (AKG) supplementation for epigenetic age reversal depends on the mitochondrial NAD+/NADH ratio, which determines whether AKG can effectively serve as a cofactor for TET enzymes or is diverted to succinate production that inhibits TET activity. In cells with a high NAD+/NADH ratio, AKG accumulates, promotes TET-mediated 5hmC generation, and facilitates DNA demethylation at senescence‑associated loci. Conversely, a low NAD+/NADH shunt favors conversion of AKG to succinate via succinate dehydrogenase, elevating intracellular succinate that competitively inhibits TET enzymes and blunts demethylation despite AKG supplementation. This redox gating explains the heterogeneous outcomes observed in human trials: middle‑aged cohorts with relatively preserved mitochondrial function show measurable epigenetic age reduction, while older individuals with accumulated mitochondrial dysfunction exhibit little or no change even at comparable AKG doses.

To test this hypothesis, we propose a stratified, double‑blind, placebo‑controlled trial in adults aged 60‑80. Participants will be grouped based on baseline mitochondrial NAD+/NADH ratio measured in peripheral blood mononuclear cells using a validated enzymatic assay. Each stratum will receive either 1 g calcium AKG daily or placebo for six months. Primary outcomes include changes in TET enzymatic activity (measured by 5hmC dot‑blot), global 5hmC levels (LC‑MS/MS), and epigenetic age (DNAm GrimAge). Secondary outcomes encompass mitochondrial respiration (Seahorse XF), plasma succinate concentrations, and markers of cellular senescence (p16^INK4a^, SASP cytokines).

Predictions: (1) In the high NAD+/NADH stratum, AKG will significantly increase TET activity, raise 5hmC, and reduce epigenetic age by ≥4 years relative to placebo; (2) In the low NAD+/NADH stratum, AKG will fail to alter TET activity or 5hmC, and epigenetic age will remain unchanged; (3) Plasma succinate will rise only in the low NAD+/NADH AKG group, correl inversely with TET activity. A negative result—namely, uniform AKG effects across redox strata or lack of succinate‑mediated TET inhibition—would falsify the model and suggest alternative mechanisms dominate AKG’s epigenetic actions in aging.

This framework integrates AKG’s known roles in the TCA cycle, mTORC1/AMPK signaling, and antioxidant capacity while adding a testable redox‑dependent layer that accounts for discrepant human data. It also directs future dosing strategies: individuals with compromised mitochondrial redox may require NAD+ boosters (e.g., NR, NMN) alongside AKG to restore TET sensitivity, a combinatorial approach ripe for subsequent investigation.